Skip to Main Content

Program

Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition

PROGRAM
All Times are EST
Program is subject to change

Friday, February 11, 2022

7:50 am Welcome and Overview / Pre-Program Test
Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Thomas A. Albini, MD
  Session I: Genetics, Histopathology, and Imaging in Non-Exudative AMD
Moderators: Philip J. Rosenfeld, MD, PhD; Giovanni Gregori, PhD; and Zohar Yehoshua, MD, MHA
Panelists: Gregory S. Hageman PhD; James G. Fujimoto, PhD; K. Bailey Freund, MD; Christine A. Curcio, PhD; Ruikang Wang, PhD; Lawrence A. Yannuzzi, MD; Giovanni Staurenghi, MD; and Frank G. Holz, MD
8:00 Chromosome 10q26–driven AMD is Associated with Reduced Expression of HTRA1 in Human RPE
Gregory S. Hageman, PhD

8:10 Ultrahigh Resolution OCT in AMD
James G. Fujimoto, PhD

8:20 How Understanding the Histologic Basis of Retinal Imaging Findings in AMD Can Improve Current and Future Patient Outcomes
K. Bailey Freund, MD

8:30 Histology and Clinical Lifecycle of Hyperreflective Foci: Implications for AMD Outcome Measures
Christine A. Curcio, PhD
8:40 Optical Attenuation as the Contrasting Mechanism in OCT Imaging and its Applications for Quantifying Choroid and Detecting RPE
Ruikang Wang, PhD
8:50 The Role of Optical Attenuation Coefficient (OAC) OCT Imaging and AMD Progression
Philip J. Rosenfeld, MD, PhD
9:00 Detachment of the Retinal Pigment Epithelium: Life Cycle
Lawrence A. Yannuzzi, MD
9:10 Extensive Macular Atrophy with Pseudodrusen: What We Know
Giovanni Staurenghi, MD

9:20 MACUSTAR: Functional Impairment and Structural Features in Intermediate AMD
Frank G. Holz, FEBO, FARVO

  Session II: Predicting Progression of AMD
Moderators: Thomas A. Albini, MD; Sander R. Dubovy, MD; and Philip J. Rosenfeld, MD, PhD
Panelists: Karl G. Csaky, MD, PhD; Emily Y. Chew, MD; Pearse A. Keane, MD; Ursula Schmidt-Erfurth, MD; and Aaron Y. Lee, MD, MSCI
9:30 The Role of Normal and Low Luminance Quantitative Contrast Sensitivity Function Testing in Predicting AMD Progression
Karl G. Csaky, MD, PhD

9:40 Artificial Intelligence/Machine Learning/Deep Learning for Detecting AMD Features and for Predicting Progression to Late AMD
Emily Y. Chew, MD

9:50 Clinically Applicable Deep-Learning Model for Detection and Quantification of Geographic Atrophy from Optical Coherence Tomography
Pearse A. Keane, MD

10:00 Therapeutic Response Pattern of GA Lesion to Pegcetacoplan
Ursula Schmidt-Erfurth, MD

10:10 Scaling Down and Scaling Up, Building Deep Learning Models for Double Layer Sign Detection
Aaron Y. Lee, MD, MSCI

  Session III: Emerging Therapies for Non-Exudative AMD
Moderators: Ninel Z. Gregori, MD; Nicolas A. Yannuzzi, MD; and Raquel Goldhardt, MD
Panelists: David S. Boyer, MD; Amir H. Kashani, MD, PhD; Nadia K. Waheed, MD, MPH; Glenn J. Jaffe, MD; Peter K. Kaiser, MD; and Justis P. Ehlers, MD
10:20 Inhibition of Connexin43 for the Treatment of AMD and Diabetic Retinopathy
David S. Boyer, MD

10:30 ReCLAIM-2: Baseline Characteristics Including Planned iRORA to cRORA and Ellipsoid Zone Methodologies
Justis P. Ehlers, MD

10:40 One Year Follow-up in a Phase 1/2a Clinical Trial of an Allogeneic RPE Cell Bioengineered Implant for Advanced Dry Age-Related Macular Degeneration
Amir H. Kashani, MD, MPH

10:50 CFI Supplementing Gene Therapy in GA Clinical Trial Update
Nadia K. Waheed, MD, MPH

11:00 Measurement Parameters and Impact of Foveal Preservation in GA Progression in the GATHER-1 Trial
Glenn J. Jaffe, MD

11:10 Novel OCT Findings Regarding “Nascent GA at Risk” and Directionality of GA Progression in the GATHER-1 Trial
Peter K. Kaiser, MD

  Session IV: C3 Inhibition for the Teatment of Geographic Atrophy
Moderators: Harry W. Flynn, Jr., MD; Philip J. Rosenfeld, MD, PhD; and Lawrence J. Singerman, MD
Panelists: Ramiro Ribeiro MD, PhD; David R. Lally, MD; Jeffrey S. Heier, MD; Charles C. Wykoff, MD; Nancy Holekamp, MD; Usha Chakravarthy, MD; and David S. Boyer, MD
11:20 C3 Inhibition for GA: Background and Rationale
Ramiro Ribeiro, MD, PhD

11:30 DERBY and OAKS Phase 3 Results
David R. Lally, MD

11:40 A Deeper Dive into the DERBY and OAKS Phase 3 Results
Jeffrey S. Heier, MD

11:50 Discussion
12:00 pm Panel Discussion on Translating the Results of Clinical Trials to the Treatment of Nonexudative AMD in the Clinics
Moderators: Philip J. Rosenfeld, MD, PhD and Lawrence J. Singerman, MD
Panelists: Pravin U. Dugel, MD; Robyn Guymer MBBS, PhD; SriniVas R. Sadda, MD; Karl G. Csaky MD, PhD; Emily Y. Chew, MD; Ramiro Ribeiro, MD PhD; Frank Holz, MD; Glenn J. Jaffe, MD; Pearse A. Keane, MD; Ursula Schmidt-Erfurth, MD; Nadia K. Waheed, MD; Peter K. Kaiser, MD; and Jeffrey S. Heier, MD
  Session V: OCT Imaging and Risk Factors for Exudative AMD
Moderators: Jorge A. Fortun, MD, PhD; Omer Trivizki, MD, MBA; and Philip J. Rosenfeld, MD, PhD
Panelists: SriniVas R. Sadda, MD; David Sarraf, MD; Giuseppe Querques, MD; Usha Chakravarthy, MD; Fenghua Wang, MD; and Nancy Holekamp, MD
12:30 Choriocapillaris and Atrophy Associated with Neovascular AMD
SriniVas R. Sadda, MD

12:40 Subretinal Fluid is Protective in Neovascular AMD: Fact or Fallacy?
David Sarraf, MD

12:50 Non-Exudative Treatment-Naive Type 3 MNV
Giuseppe Querques, MD

1:00 Ocular and Systemic Risk Factors for Progression to Exudation in the EDNA Trial
Usha Chakravarthy, MD

1:10 The Predictable Factors for Recurrence of Polypoidal Choroidal Vasculopathy using OCT Anogiograhpy?
Fenghua Wang, MD

1:20 Home OCT Based Tracking of Neovascular AMD Disease Dynamics and Treatment Response
Nancy Holekamp, MD

1:30 Adjourn until Saturday Feb. 12th at 8:00 am

Saturday, February 12, 2022

7:50 am Welcome and Overview
Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Thomas A. Albini, MD
  Session VI: Emerging and Current Therapies for Exudative AMD
Moderators: Janet L. Davis, MD; Thomas A. Albini, MD; and Jaclyn Kovach, MD
Panelists: Daniel F. Martin, MD; Robert Bhisitkul, MD; Arshad M. Khanani, MD, MA; Jay S. Duker, MD; Andrew A. Moshfeghi, MD, MBA; Allen C. Ho, MD; Thomas A. Ciulla, MD, MBA; David M. Brown, MD; Charles C. Wykoff, MD, PhD; Peter A. Campochiaro, MD; David Eichenbaum, MD; Michael S. Ip, MD; and Rahul Khurana, MD
8:00 Long Term Outcomes in Neovascular AMD: What We Know and What We Don’t
Daniel F. Martin, MD

8:10 Phase 1 Study of Intravitreal UBX1325: A Novel Agent Against Retinal Cell Senescence in AMD and DME
Robert Bhisitkul, MD
8:20 6-month Results of a Tyrosine Kinase Inhibitor (Vorolanib) in a Bio-erodible Durasert Implant for Previously Treated Wet AMD: The DAVIO Trial
Jay S. Duker, MD
8:30 Safety and Durability of Intravitreal Sunitinib Malate Depot (GB-102) in Wet Age-Related Macular Degeneration (ALTISSIMO, Phase 2B)
Veeral S. Sheth, MD, MBA
8:40 Update on OTX-TKI Clinical Trials for Macular Disease
Andrew A. Moshfeghi, MD, MBA

8:50 Update on 4D-150: Inhibition of VEGF A, B, C and PlGF Using Intravitreal, Dual Transgene AAV Gene Therapy for Neovascular AMD
Arshad M. Khanani, MD, MA

9:00 RGX-314 Gene Therapy for Wet AMD
Allen C. Ho, MD

9:10 The Suprachoroidal Space and Suprachoroidal Delivery for Clinicians
Thomas A. Ciulla, MD, MBA

9:20 Update on the AAVIATE Phase 2 Study: Suprachoroidal RGX-314 in Neovascular AMD
Rahul N. Khurana, MD

9:30 CANDELA: High Dose Aflibercept for Neovascular AMD
David M. Brown, MD

  Ranibizumab Port Delivery System
9:40 2-Year Outcomes from the Phase 3 Archway Trial: Management of Neovascular Age-Related Macular Degeneration using the Ranibizumab Port Delivery System
Charles C. Wykoff, MD, PhD

9:48 Long Term (3+ Year) Safety and Efficacy Data for the Port Delivery System
David Eichenbaum, MD

9:56 Patient Level Analysis of the PDS versus Monthly Injections in Neovascular AMD
Peter A. Campochiaro, MD

10:04 Discussion of Previous PDS Talks
10:10 A Treatment-Agnostic Analysis of the Long-Term Impact of IRF and SRF on Vision and Anatomy in Neovascular AMD in the HAWK and HARRIER Studies
Michael S. Ip, MD

  Session VII: Dual Inhibition of Ang2 and VEGF for the Treatment of Exudative AMD and DME–An Update from the Faricimab Program
Moderators: Philip J. Rosenfeld, MD, PhD; Lawrence J. Singerman, MD; and Harry W. Flynn, Jr., MD
Panelists: Jeffrey S. Heier, MD; Robyn Guymer, MBBS, PhD; John A. Wells, III, MD; Thomas A. Albini, MD; Jennifer Sun, MD; Arshad Khanani, MD; and Usha Chakravarthy, MD
10:28 Overview of Faricimab for Exudative Retinal Diseases: nAMD, DME, and RVO
Jeffrey S. Heier, MD

10:33 Faricimab Update in nAMD
Robyn Guymer, MBBS, PhD

10:38 Faricimab in DME: 2 Year Data of the Yosemite/Rhine Phase 3 Studies
John A. Wells, III, MD

10:48 Discussion
  Session VIII: Diabetic Retinopathy-Imaging and Staging
Moderators: Justin H. Townsend, MD; Harry W. Flynn, Jr. MD; and Philip J. Rosenfeld, MD, PhD
Panelists: Seung-Young Yu, MD; Jennifer Sun, MD; Anat Loewenstein, MD; Ramin Tadayoni, MD, PhD; Jonathan F. Russell, MD, PhD; and Toshinori Murata, MD, PhD
11:00 OCT Angiography in Diabetic Retinopathy
Harry W. Flynn, Jr., MD

11:10 SS-OCTA Imaging for Determining Severity of Diabetic Retinopathy
Seung-Young Yu, MD

11:20 Can Capillary Non-Perfusion on OCTA Be a Substitute for Color Photographs in DR Classification?
Ramin Tadayoni, MD, PhD

11:30 Toward a New Staging System for Diabetic Retinopathy Using Widefield Swept-Source Optical Coherence Tomography Angiography
Jonathan F. Russell, MD, PhD

11:40 Detection of Diabetic Retinopathy from Ultra-Wide Field Scanning Laser Ophthalmoscope Images: A Multi-Center Deep-Learning Analysis
Anat Loewenstein, MD

11:50 Updating the Diabetic Retinal Disease Staging System
Jennifer Sun, MD

  Session IX: Diabetic Retinopathy-Treatment
Moderators: Harry W. Flynn, Jr., MD; Jayanth Sridhar, MD; and William E. Smiddy, MD
Panelists: Michael A. Klufas, MD; Diana V. Do, MD; Mark R. Barakat, MD; Carl D. Regillo, MD; Arshad M. Khanani, MD, MA; and Peter K. Kaiser, MD
12:00 pm APX3330, a Phase 2 Oral Drug Inhibiting Novel Target Ref-1 with a Dual Anti-VEGF and Anti-inflammatory MOA for the Treatment of Diabetic Retinal Diseases
Peter K. Kaiser, MD

12:10 Phase 2 Results of THR-149 in Patients with DME: KALAHARI Study Part A
Arshad M. Khanani, MD, MA

12:20 Suprachoroidal RGX-314 Gene Therapy for Diabetic Retinopathy
Michael A. Klufas, MD

12:30 Intact Perifoveal Capillaries Confirmed by OCT-Angiography Leads to Successful Anti-VEGF Treatment for Diabetic Macular Edema and Branch Retinal Vein Occlusion
Toshinori Murata, MD, PhD

12:40 Identifying Predictive Factors for Response to Aflibercept in the PANORAMA Study
Diana V. Do, MD

12:50 52-week Results from KINGFISHER, a Phase III Study with q4w Dosing of Brolucizumab 6 mg in DME
Mark R. Barakat, MD

1:00 Brolucizumab for the Treatment of DME: 100-Week Results from the Two Pivotal Phase III KESTREL and KITE studies
Carl D. Regillo, MD

  Session X: Retinal and Choroidal Vasculopathies and Degenerations
Moderators: Philip J. Rosenfeld, MD, PhD; Audina M. Berrocal, MD; and Stephen G. Schwartz, MD, MBA
Panelists: Byron L. Lam, MD; Richard F. Spaide, MD; Darius M. Moshfeghi, MD; Carel B. Hoyng, MD; Quan Dong Nguyen, MD, MSc; Baruch D. Kuppermann, MD, PhD; Martin Friedlander, MD, PhD; and Prashanth G. Iyer, MD, MPH
1:10 What's New with MacTel2
Martin Friedlander, MD, PhD

1:20 Overview of Venous Overload Choroidopathy
Richard F. Spaide, MD

1:30 Aflibercept for Retinopathy of Prematurity: Firefleye Trial
Darius M. Moshfeghi, MD

1:40 Bruch's Membrane and Choriocapillaris Imaging in Sorsby Macular Dystrophy
Prashanth G. Iyer, MD, MPH

1:50 Stargardt Disease, Towards Therapy
Carel B. Hoyng, MD

2:00 Tinlarebant, an RBP4 (Retinol Binding Protein 4) Antagonist, for Stargardt Disease
Quan Dong Nguyen, MD, MSc

2:10 Intravitreal Retinal Progenitor Cells for the Treatment of Retinitis Pigmentosa
Baruch D. Kuppermann, MD, PhD

2:20 Treatment Update for Inherited Retinal Degenerations
Byron L. Lam, MD

2:30 Post-Program Test and Closing Remarks